Business Description
Seagen Inc
NAICS : 325414
SIC : 2836
ISIN : US81181C1045
Share Class Description:
SGEN: Ordinary SharesCompare
Compare
Traded in other countries / regions
SGEN.USASGT.GermanyS1GE34.Brazil0A8R.UKSGEN.Mexico IPO Date
2001-03-07Description
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.29 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.15 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 26.81 | |||||
| Beneish M-Score | -2.48 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 24.3 | |||||
| 3-Year EBITDA Growth Rate | -36.5 | |||||
| 3-Year EPS without NRI Growth Rate | -50.9 | |||||
| 3-Year FCF Growth Rate | -26.6 | |||||
| 3-Year Book Growth Rate | 11.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 16.32 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.01 | |||||
| 9-Day RSI | 60.33 | |||||
| 14-Day RSI | 62.49 | |||||
| 6-1 Month Momentum % | 1.6 | |||||
| 12-1 Month Momentum % | 49.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | |||||
| Quick Ratio | 2.66 | |||||
| Cash Ratio | 1.69 | |||||
| Days Inventory | 297.83 | |||||
| Days Sales Outstanding | 84.7 | |||||
| Days Payable | 105.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.7 | |||||
| Shareholder Yield % | -0.04 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 76.46 | |||||
| Operating Margin % | -34.78 | |||||
| Net Margin % | -33.55 | |||||
| ROE % | -26.09 | |||||
| ROA % | -20.19 | |||||
| ROIC % | -55.77 | |||||
| ROC (Joel Greenblatt) % | -112.23 | |||||
| ROCE % | -26.23 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 18.29 | |||||
| PB Ratio | 15.2 | |||||
| Price-to-Tangible-Book | 18.8 | |||||
| EV-to-EBIT | -51.33 | |||||
| EV-to-Forward-EBIT | -243.7 | |||||
| EV-to-EBITDA | -57.9 | |||||
| EV-to-Forward-EBITDA | -434.7 | |||||
| EV-to-Revenue | 17.85 | |||||
| EV-to-Forward-Revenue | 12.07 | |||||
| EV-to-FCF | -53.44 | |||||
| Price-to-Median-PS-Value | 1.06 | |||||
| Price-to-Net-Current-Asset-Value | 24.28 | |||||
| Price-to-Net-Cash | 95.59 | |||||
| Earnings Yield (Greenblatt) % | -1.95 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SGEN
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Seagen Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,162.001 | ||
| EPS (TTM) ($) | -3.89 | ||
| Beta | -0.04 | ||
| Volatility % | 37.07 | ||
| 14-Day RSI | 62.49 | ||
| 14-Day ATR ($) | 2.267107 | ||
| 20-Day SMA ($) | 208.689 | ||
| 12-1 Month Momentum % | 49.77 | ||
| 52-Week Range ($) | 116.08 - 217.08 | ||
| Shares Outstanding (Mil) | 187.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Seagen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Seagen Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Seagen Inc Frequently Asked Questions
What is Seagen Inc(SGEN)'s stock price today?
The current price of SGEN is $212.20. The 52 week high of SGEN is $217.08 and 52 week low is $116.08.
When is next earnings date of Seagen Inc(SGEN)?
The next earnings date of Seagen Inc(SGEN) is 2023-10-27 Est..
Does Seagen Inc(SGEN) pay dividends? If so, how much?
Seagen Inc(SGEN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers